2025/02/20
Fostrox - Final safety and efficacy results from the phase 1b/2a study of fostrox plus lenvatinib in second/third line advanced hepatocellular carcinoma progressed on immunotherapy
2024/06/27
Fostrox - Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma
2024/01/19
Fostrox - First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC)
2023/09/07
Fostrox - Combinations of fostrox (MIV-818), a novel nucleotide prodrug, with lenvatinib or sorafenib shows increased efficacy in nonclinical hepatocellular carcinoma (HCC) models in vivo
2023/04/17
Fostrox - A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo
2022/11/11
Fostrox (MIV-818) in combination with anti-PD-1 shows increased efficacy in nonclinical tumor models in vivo
2022/02/04
Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver
2021/09/13
MIV-818 1b Abstract at ESMO 2021
2019/11/04
MIV-818 stimulates an anti-tumor immune response in vitro and enhances the effects of pembrolizumab
2019/10/16
Analgesic effects of the cathepsin K inhibitor
2019/06/02
Determination of the Recommended Phase 2 Dose of birinapant in combination with pembrolizumab: Results from the dose escalation phase of BPT-201
2019/05/13
An Open-label Phase 2 Clinical Trial of Topical Remetinostat for Basal Cell Carcinoma (poster)
2019/05/13
An Open-label Phase 2 Clinical Trial of Topical Remetinostat for Basal Cell Carcinoma (presentation)
2019/05/06
Safety and Efficacy of Six Months´ Open Label Extension Post-RCT Using the Novel Cathepsin K Inhibitor MIV-711 in Patients with Osteoarthritis
2018/12/01
5-Fluorotroxacitabine displays potent anti-leukemic effects and circumvents resistance to Ara-C
Poster presented at the ASH annual meeting in San Diego, USA.
Poster presented at the ASH annual meeting in San Diego, USA.
2018/11/14
Suppression of Regulatory T cells (Tregs) in vivo by Small Molecule Targeting of the Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1)
Poster presented at the 30th EORTC-NCI-AACR symposium in Dublin, Ireland
2018/11/14
Characterization of small molecule inhibitors of ubiquitin specific peptidase 1 (USP1) as anti-cancer agents
Poster presented at the 30th EORTC-NCI-AACR symposium in Dublin, Ireland.
2018/10/15
The Potential Clinical Relevance of Imaging Biomarker Data from Short Term Interventional Trials in Osteoarthritis
2018/09/25
Identification and characterization of novel small molecule inhibitors of ubiquitin specific peptidase 1 (USP1)
Poster presented at the 16th Annual Discovery on Target i Boston, USA
2018/08/27
Selective Suppression of Regulatory T-cell Development with Small Molecule Inhibitors of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1)
Poster presented at the Immuno-Oncology SUMMIT (#IOSummit) in Boston, USA.
2018/06/04
A phase 1/2 study with birinapant in combination pembrolizumab
Poster presented at the ASCO annual meeting in Chicago, USA.
2018/05/19
Anti-pruritic properties of Remetinostat (SHAPE), a topical HDAC inhibitor
Presented at the International Investigative Dermatology meeting (IID) in Orlando, USA.
2018/04/17
Synergistic and additive anti-tumor effects of MIV-818 in combination with sorafenib in nonclinical hepatocellular carcinoma models
Presented at the annual meeting for the American Association for Cancer Research (AACR) in Chicago.
2018/03/19
The selective cathepsin K inhibitor MIV‑711 attenuates joint pathology in experimental animal models of osteoarthritis
Article published in Journal of Translational Medicine 2018.
2018/03/02
The biomarker potential of Ki67 and pH2AX immunohistochemistry in guiding use of the liver-targeting nucleotide MIV-818 in patients with hepatocellular carcinoma
2018/03/02
Liver targeting and anti-tumourefficacy of the nucleotide prodrug MIV-818 in nonclinical models of hepatocellular carcinoma
2017/11/08
MIV-711, a novel cathepsin K inhibitor demonstrates evidence of osteoarthritis structure modification
Presented at the Annual Meeting of the American College for Rheumatology in San Diego, USA.
2017/09/27
Evaluation and characterization of small molecule inhibitors of deubiquitinating enzyme USP14 as potential anti-cancer agents
2017/05/25
Discovery of b-D-20-deoxy-20-dichlorouridine nucleotide prodrugs as potent inhibitors of hepatitis C virus replication
2017/04/28
Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers
Presented at the EASL International Liver Congress in Amsterdam, Netherlands.
2017/04/19
MIV-802, a uridine nucleotide prodrug, is a more potent inhibitor of HCV genotype 3 replication than sofosbuvir
Presented at EASL, International Liver Congress in Amsterdam, Netherlands.
2017/04/05
Defining exposure-PD and efficacy relationships with the novel liver-targeting nucleotide prodrug MIV-818 for the treatment of liver cancers
Presented at the American Association for Cancer Research Annual Meeting in Washington, D.C., USA.
2017/02/15
Selective targeting of the liver with nucleotide prodrugs for the treatment of liver cancers
Presented at the 26th conference of Asian Pacific Association for the study of the liver in Shanghai, China.
2016/10/03
Discovery of potent small molecule inhibitors of RSV Fusion protein
Presented at the 10th International Respiratory Syncytial Virus Symposium in Argentina.
2016/09/10
Selective targeting of the liver with nucleotide prodrugs for the treatment of liver cancers
Presented at the International Liver Cancer Association 10th Annual Conference in Canada.
2016/06/10
Phosphoramidate prodrugs of uridine analogs, including sofosbuvir, are metabolized to both uridine and cytidine triphosphates in Huh7 cells and primary human hepatocytes
Presented at the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy in Washington DC, USA.
2016/04/20
The Cathepsin K inhibitor L-006235 demonstrates both disease modification and attenuation of pain behavior in the MIA model of osteoarthritis
Presented at the OARSI 2016 World Congress in Amsterdam, Netherlands.
2015/04/22
Preclinical characterisation of MIV-802, a novel uridine nucleotide HCV NS5b polymerase inhibitor, for treatment of hepatitis C virus infection